EyePoint Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 214

Employees

  • Stock Symbol
  • EYPT

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.23
  • (As of Friday Closing)

EyePoint General Information

Description

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Contact Information

Formerly Known As
pSivida
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 480 Pleasant Street
  • Suite C-400
  • Watertown, MA 02472
  • United States
+1 (833)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 480 Pleasant Street
  • Suite C-400
  • Watertown, MA 02472
  • United States
+1 (833)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EyePoint Stock Performance

As of 20-Nov-2026, EyePoint’s stock price is $0.23. Its current market cap is $26.6M with 114M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.23 $0.26 $0.23 - $19.11 $26.6M 114M 8.37M -$3.96

EyePoint Financials Summary

As of 30-Sep-2026, EyePoint has a trailing 12-month revenue of $2.58M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 121,256 1,329,802 276,599 998,897
Revenue 2,579 31,371 43,273 46,018
EBITDA (349,039) (241,125) (144,314) (75,914)
Net Income (342,523) (231,962) (130,870) (70,795)
Total Assets 166,137 363,996 418,465 355,184
Total Debt 19,124 20,772 21,858 4,906
Public Fundamental Data provided by Morningstar, Inc. disclaimer

EyePoint Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EyePoint‘s full profile, request access.

Request a free trial

EyePoint Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeut
Drug Discovery
Watertown, MA
214 As of 2026

San Rafael, CA
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EyePoint Competitors (56)

One of EyePoint’s 56 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioMarin Pharmaceutical Formerly PE-Backed San Rafael, CA
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
The Zambon Group Private Debt Financed Bresso, Italy
Voyager Therapeutics Formerly VC-backed Lexington, MA
PulseSight Therapeutics Venture Capital-Backed Paris, France
You’re viewing 5 of 56 competitors. Get the full list »

EyePoint Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyePoint Investments & Acquisitions (3)

EyePoint’s most recent deal was a Corporate Asset Purchase with Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) for . The deal was made on 17-Aug-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) 17-Aug-2021 Corporate Asset Purchase Buildings and Property
Icon Bioscience 28-Mar-2018 Merger/Acquisition Drug Delivery
Control Delivery Systems 30-Dec-2005 Merger/Acquisition Drug Delivery
To view EyePoint’s complete investments and acquisitions history, request access »

EyePoint ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.2 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view EyePoint’s complete esg history, request access »

EyePoint FAQs

  • When was EyePoint founded?

    EyePoint was founded in 1987.

  • Where is EyePoint headquartered?

    EyePoint is headquartered in Watertown, MA.

  • What is the size of EyePoint?

    EyePoint has 214 total employees.

  • What industry is EyePoint in?

    EyePoint’s primary industry is Drug Discovery.

  • Is EyePoint a private or public company?

    EyePoint is a Public company.

  • What is EyePoint’s stock symbol?

    The ticker symbol for EyePoint is EYPT.

  • What is the current stock price of EyePoint?

    As of 20-Nov-2026 the stock price of EyePoint is $0.23.

  • What is the current market cap of EyePoint?

    The current market capitalization of EyePoint is $26.6M.

  • What is EyePoint’s current revenue?

    The trailing twelve month revenue for EyePoint is $2.58M.

  • Who are EyePoint’s competitors?

    BioMarin Pharmaceutical, Foventa Therapeutics, The Zambon Group, Voyager Therapeutics, and PulseSight Therapeutics are some of the 56 competitors of EyePoint.

  • What is EyePoint’s annual earnings per share (EPS)?

    EyePoint’s EPS for 12 months was -$3.96.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process